Author(s)

Zilong Kuang, Souly Leng, Fanyu Li

Corresponding Author

Zilong Kuang

ABSTRACT

Alzheimer's disease is a devastating neurodegenerative disease, and the most common form of dementia. Alzheimer's disease (AD) is the leading cause of mortality in the United States, affecting 50 million people worldwide. Alzheimer's disease (AD) is characterized by the deposition of intracerebral amyloid beta (Aβ) plaques and neurofibrillary tangles accompanied by synaptic dysfunction and neurodegeneration. However, traditional treatments are limited and cannot treat the disease or relieve symptoms. In recent years, significant advances have been made in understanding its pathogenesis, diagnostic methods, and treatment of this disease. Aduhelm is an amyloid beta-directed antibody used in the treatment of Alzheimer's disease, and the first drug to be approved as a potential disease regulator. The reduction of amyloid beta plaques was utilized as an alternative endpoint in its accelerated approval. Aduhelm reduced the development of amyloid beta plaques in the brain. Clinical trials data show that Aduhelm drug is associated with significant reductions in A-PET signal in the brains of Alzheimer's disease patients. However, Aduhelm seems to reduce MMSE and CDR-SB deterioration in a dose-dependent way. Some research showed that Aduhelm decreased amyloid accumulation in six cortical regions in a dose and time dependent manner. This paper introduces the current situation of AD, briefly introduces its pathogenesis, summarizes its clinical research, and the controversy over the efficacy and/or safety of Aduheim in Alzheimer's disease. Aduhelm may be promising drugs for a wide range of treatments in the future. This is an important step forward and this focus, attention and discussion of Alzheimer's is expected to bring about many changes.

KEYWORDS

Alzheimer's disease (AD), Aduhelm, Clinical trials, amyloid beta (Aβ) plaques